Short answer
Edgewise Therapeutics, Inc. (EWTX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). No fiscal-year 2026 operating results or financial metrics available for investor analysis.
Edgewise Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- No fiscal-year 2026 operating results or financial metrics available for investor analysis
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $57.3M, or $0.53 per share, versus $36.1M, or $0.34, in Q2 2025
- Cash, equivalents and marketable securities $460.7M at June 30; pro forma $2.01B after $1.55B Servier upfront proceeds
- Servier acquired sevasemten and the muscular dystrophy business for $1.55B upfront plus up to $1.1B milestones
- Positive 12-week Phase 2 CIRRUS-HCM data supports EDG-7500 Phase 3 initiation expected in Q4 2026
- R&D expense rose to $47.5M from $33.6M as EDG-7500 and EDG-15400 clinical activity accelerated
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Edgewise Therapeutics, Inc. 8-K filings
Get the next EWTX 8-K as it lands
Follow EWTX for push alerts, or ask the research agent what this filing means.